Ocugen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCGN research report →
About the company
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis.
- CEO
- Shankar Musunuri
- IPO
- 2014
- Employees
- 95
- HQ
- Malvern, PA, US
Price Chart
- Market Cap
- $511.17M
- P/E
- -6.48
- P/S
- 114.48
- P/B
- 83.35
- EV/EBITDA
- -7.99
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1483.85%
- Net Margin
- -1605.22%
- ROE
- -127987.50%
- ROIC
- -157.55%
- Revenue
- $4.41M · 8.83%
- Net Income
- $-67,846,000 · -25.52%
- EPS
- $-0.23 · -15.00%
- Op Income
- $-62,916,000
- FCF YoY
- -25.53%
- 52W High
- $2.73
- 52W Low
- $0.91
- 50D MA
- $1.43
- 200D MA
- $1.55
- Beta
- 2.18
- Avg Volume
- 7.86M
Get TickerSpark's AI analysis on OCGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Johnson-Greene Treerita Essalima | buy | 21,000 |
| Jun 11, 26 | Kompella Uday | other | 170,100 |
| Jun 11, 26 | Chandrasekhar Satishchandran | other | 170,100 |
| Jun 11, 26 | Castillo Kirsten | other | 170,100 |
| Jun 11, 26 | Zhang Junge | other | 170,100 |
| Jun 11, 26 | Coleman Blaise | other | 170,100 |
| Apr 1, 26 | Zhang Junge | other | 66,929 |
| Apr 1, 26 | Zhang Junge | other | 112,205 |
| Apr 1, 26 | Zhang Junge | other | 15,000 |
| Apr 1, 26 | Zhang Junge | other | 15,000 |
Our OCGN coverage
Recent articles, reports, and earnings notes.
No research on OCGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCGN report →Similar companies
Peers in the same neighborhood.